NeoGenomics, Inc.
As of Oct 22, 2026, NeoGenomics is in Stage 2, the uptrend phase, now in week 16 (since Jul 2, 2026). It closed at $16.39, 17.7% below its 52-week high and above its 200-day average, which is rising.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care
Is NEO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NEO among Diagnostics & Research9th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| 9 | NEO | Stage 2 · wk 16 | 88 | −10.7% |
NeoGenomics: quick answers
What stage is NeoGenomics in?
As of Oct 22, 2026, NeoGenomics (NEO) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 2, 2026 and is in week 16. What the four stages mean
Is NeoGenomics in an uptrend?
Yes. NeoGenomics is in a Stage 2 uptrend. It trades 29.6% above its 200-day average, which is rising.
How far is NeoGenomics from its 52-week high?
NeoGenomics closed at $16.39 on Oct 22, 2026, 17.7% below its 52-week high of $19.91. Its 52-week low is $7.19.
How has NeoGenomics performed over the past year?
As of Oct 22, 2026, NeoGenomics is up 57.1% over the past year and up 39.4% so far in 2026.
Which sector and industry is NeoGenomics in?
NeoGenomics is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.